This data note reviews data currently available at the federal and state level on race/ethnicity of booster shot recipients of COVID-19 vaccines.
- view as grid
- view as list
This report finds the public is generally supportive of U.S. distribution of vaccines internationally, though more likely to prefer the U.S. playing a major role versus a leading one, and there are partisan differences. The analysis also examines how different information affects the public’s views.
Efforts to Increase Marketplace Enrollment During Open Enrollment Could Boost Medicaid Coverage, Too
As the ninth open enrollment period for the Health Insurance Marketplaces begins, enhanced Marketplace premium help along with increased funding for outreach and enrollment assistance mean there are more affordable coverage options for the millions of people who remain uninsured and more help available to connect those individuals to coverage.
In this brief, we examine the various interrelated factors that have contributed to rapid home test scarcity in the U.S. There are several interrelated factors that impact the availability of rapid home COVID-19 tests. These range from the regulatory environment to the supply chain to federal investment and messaging to affordability.
Federal Policy May Temporarily Close the Coverage Gap, But Long-term Coverage May Fall Back to States
Recent policy attention has focused on closing the coverage gap for roughly 2.2 million individuals living in the 12 states that have not adopted Medicaid expansion included in the Affordable Care Act (ACA). These individuals do not qualify for Medicaid and have incomes below poverty, making them ineligible for premium subsidies in the…
This analysis highlights state-level data on the status of the Title X family planning program on the eve of the implementation of the new Biden Administration regulations for the program.
Rebuilding the Title X Family Planning Network Will Take Time, Despite Biden Administration Actions Issuing New Regulations and Additional Funding
A new KFF analysis highlights state-level data on the status of the Title X family planning program on the eve of the implementation of the new Biden Administration regulations for the program. To date, five states still have no Title X clinics, and seven states are still operating with less…
A Record 3,834 Medicare Advantage Plans Will be Available in 2022, Up 8 Percent From 2021, While the Number of Medicare Part D Stand-Alone Plans is Decreasing Mainly Due to Firm Consolidations
A record 3,834 Medicare Advantage plans will be available across the country as alternatives to traditional Medicare for 2022, a new KFF analysis finds. That’s an increase of 8 percent from 2021, and the largest number of plans available in more than a decade. At the same time, the number…
For 2022, the average Medicare beneficiary has access to 39 Medicare Advantage plans, the largest number of options available in the last decade, and can choose from plans offered by nine firms. Among the majority of Medicare Advantage plans that cover prescription drugs, 59 percent will charge no premium in addition to the monthly Medicare Part B premium. As in previous years, the vast majority of Medicare Advantage plans will offer supplemental fitness, dental, vision, and hearing benefits. In addition, virtually all will also offer telehealth benefits in 2022.
This issue brief provides an overview of the Medicare Part D prescription drug benefit market for 2022, with a primary focus on stand-alone drug plans. It includes national and state-level data on plan availability, premiums, benefit design, cost sharing, information about premium-free plans for low-income beneficiaries, and information about the national Part D drug plans available in 2022.